Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-539313 in Moderate to Severe Binge Eating Disorder
NCT04753164Phase 2Completed
- Sponsor
- Idorsia
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivasorexant in binge eating disorder (BED), sponsored by Idorsia. Started Feb 2021; status: completed.
02
Drugs
nivasorexant
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT04753164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753164.